Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Aortoiliac Occlusive Disease Treatment & Management

  • Author: Kenneth E McIntyre, Jr, MD; Chief Editor: Vincent Lopez Rowe, MD  more...
 
Updated: Jul 20, 2015
 

Approach Considerations

Treatment of patients with peripheral arterial disease (PAD) has two goals. The first and foremost goal is to reduce the risk of vascular events (myocardial infarction [MI], stroke, vascular death) that occur at an alarmingly high rate in patients with PAD. About 30% of patients with PAD die within 5 years, and death is usually due to an ischemic coronary event.

The second goal of treatment is to improve symptoms in those patients with claudication and prevent amputation in patients with critical limb ischemia. Critical limb ischemia is present when patients have symptoms of ischemic rest pain, nonhealing foot ulcers, or gangrene, and its presence mandates urgent evaluation with aortography and endovascular and/or surgical revascularization to prevent limb loss.

At least 50% of patients with PAD may be asymptomatic. Because natural history data are poor for iliac stenosis, surgical and/or endovascular intervention should not be considered if patients truly are asymptomatic. Surgical intervention for limb-threatening ischemia is accepted universally, unless the limb is deemed nonviable. Determining whether or not to intervene in a patient with mild claudication may not be as straightforward.

No controversy exists regarding the appropriate surgical procedure to treat aortoiliac occlusive disease (AIOD). Use thromboendarterectomy (TEA) only in cases of type I atherosclerosis. TEA also is an excellent option for those patients with blue toe syndrome from severe ulcerogenic aortoiliac atherosclerosis that involves only the infrarenal aorta and common iliac arteries. Some authors have advocated performing the aortic procedure through a retroperitoneal rather than an intra-abdominal approach. Despite some excellent work in this area, outcomes have generally been similar whether the procedure is performed in a retroperitoneal or a transabdominal fashion.

An important role exists for conservative therapy in patients with AIOD. Although surgical therapy usually alleviates symptoms, the patient must be apprised of the operative risk of mortality (2-3%), as well as anticipated outcomes over time. Since the advent of catheter-based treatments for AIOD, asymptomatic patients are often treated prophylactically with either angioplasty or stenting of iliac arterial lesions that are discovered during coronary angiography. This practice of drive-by angioplasty should not be recommended.

It seems clear that angioplasty and/or stent placement is a suitable alternative for patients with very focal occlusive disease in the common iliac artery but offers a poor alternative for more diffuse disease that involves the external iliac artery. Furthermore, the patency results for patients who have had total occlusions in the iliac arteries treated by endovascular therapy are definitely inferior to conventional surgical results.

Controversy remains regarding the appropriate place for minimally invasive treatment of AIOD. Laparoscopically assisted aortobifemoral bypasses (AFBs) have been performed in both animals and humans with satisfactory results. However, a significant learning curve seems to be involved, and no long-term follow-up data are available for review.

Society for Vascular Surgery practice guidelines

In March 2015, the Practice Guidelines Committee of the Society for Vascular Surgery issued specific practice recommendations for the treatment of asymptomatic PAD and intermittent claudication in patients with atherosclerotic disease of the lower extremities.[8] Among the recommendations were the following:

  • Emphasis is placed on risk factor modification, medical therapies, and broader use of exercise programs to improve cardiovascular health and functional performance
  • Screening for PAD appears of unproven benefit at present
  • Revascularization for intermittent claudication is appropriate for selected patients with disabling symptoms, after a careful risk-benefit analysis; treatment should be individualized according to comorbid conditions, degree of functional impairment, and anatomic factors
  • Invasive treatments for intermittent claudication should provide predictable functional improvements with reasonable durability (suggested minimum threshold, >50% chance of sustained efficacy for ≥2 years); anatomic patency is considered a prerequisite for sustained efficacy
  • Endovascular approaches are favored for most candidates with aortoiliac disease
  • Caution is warranted with interventions for intermittent claudication when durability is limited (eg, extensive calcification, small-caliber arteries, diffuse infrainguinal disease, poor runoff); in such cases (if patients are otherwise good-risk) and in cases of previous endovascular failure, surgical bypass may be preferred
  • Patients who undergo invasive treatments for intermittent claudication should be monitored regularly in a surveillance program
Next

Medical Therapy

Three fundamental principles are involved in the treatment of symptomatic PAD due to AIOD.

First, the risk factors must be identified and aggressively treated. The two most important risk factors for PAD are cigarette smoking and diabetes. Complete cessation of smoking is mandatory. Carefully regulate serum glucose; the goal is a glycosylated hemoglobin (HbA1c level) below 7%. The goal of hypertension control should be blood pressures lower than 140/90 mm Hg. The low-density lipoprotein (LDL) cholesterol level should be reduced to less than 100 mg/dL, usually with hepatic 3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitors (statins). In addition to modification of risk factors, patients with AIOD should receive lifelong antiplatelet therapy to reduce the risk of MI, stroke, and vascular death.

Second, initiate a walking exercise program. Numerous prospective randomized clinical trials have attested to the efficacy of walking exercise to treat claudication.[9, 10] Every trial has demonstrated improvements of 180-340% in walking distance . Supervised walking programs usually produce better results than unsupervised exercise does. Walking exercise even has been compared to angioplasty and found to produce superior results. Walking exercise improves symptoms of claudication because the muscle enzymes involved in oxygen extraction and utilization become more efficient over time.

Finally, two pharmacologic agents approved by the US Food and Drug Administration (FDA) may alleviate the symptoms of claudication caused by lower-extremity arterial occlusive disease. Pentoxifylline is a methylxanthine derivative that acts as a hemorheologic agent, lowering blood viscosity. Unfortunately, it is effective in only 30-40% of patients and must be taken three times daily. If it is effective, walking distances only improve modestly. Cilostazol, a phosphodiesterase III inhibitor, has been shown to be more effective than either pentoxifylline or placebo. Its mechanism of action is not well understood. Adverse effects may include headache and loose stools, but the medication generally is well tolerated. It should not be used in patients with significant congestive heart failure.

Previous
Next

Surgical Therapy

Choice of surgical procedure

Direct arterial reconstruction on the diseased aortoiliac arterial segment is well established. Aortoiliac TEA and AFB are the two traditional means of surgically treating AIOD. The two procedures have similar risks and results, and the outcomes have stood the test of time. In 1966, Blaisdell introduced axillofemoral bypass as an extra-anatomic technique for improving inflow to the lower extremities without the need for an abdominal procedure.[11] Since then, with the advent of arterial stents, endovascular repair of aortoiliac lesions has become a reasonable alternative to consider if the pathologic anatomy is suitable.[12, 13]

TEA of the aorta and iliac arteries was the first reconstructive procedure performed for AIOD. The concept is simple. A dissection plane exists between the arterial media and the obstructing plaque. When the appropriate plane is entered, the arterial intima, plaque, and internal elastic lamina of the media are removed as a single specimen.

Early in the experience, surgeons were concerned that the remaining portion of arterial wall was not sturdy enough to hold blood under arterial pressure. With more experience, however, it became clear that the remaining portion of the vessel (external elastic lamina of the media and adventitia) following TEA provided a secure and durable conduit with excellent long-term patency. When aortoiliac TEA is used to treat patients with type I atherosclerotic occlusive disease, the patency rates are excellent. However, the results are not as good when TEA is applied to patients with more extensive distal occlusive lesions in the external iliac and femoral arteries.

Today, aortoiliac TEA is not used as commonly as AFB is, primarily because the procedure is best suited for patients who have type I atherosclerosis with occlusive disease limited to the infrarenal aorta and common iliac arteries (see the image below). Patients with type 1 atherosclerosis comprise the minority of patients with PAD. Furthermore, younger surgeons may not have had proper exposure to the technique of aortoiliac TEA during their training and therefore may not have appropriate experience using the procedure to treat AIOD.

Type I atherosclerosis with occlusive disease limi Type I atherosclerosis with occlusive disease limited to the infrarenal aorta and common iliac arteries.

Aortoiliac TEA has significant advantages over conventional AFB for the treatment of AIOD. The first, and most obvious, is that prosthetic material is not needed to perform the arterial reconstruction. Even for the most experienced surgeons, aortic prosthetic graft infections occur in 0.5-3% of patients following AFB. The mortality associated with the treatment of aortic graft infection ranges from 11-27%. In addition, a similar mortality is observed for early amputation following aortic graft infection.

Many patients undergo aortoiliac TEA not for removal of the plaques that obstruct blood flow but, rather, for removal of the source of atheroembolism causing blue toe syndrome. Aortoiliac TEA is ideally suited for this indication because the offending degenerated atheroma is removed, leaving a clean, glistening surface that soon is covered by new functional endothelium.

The only significant disadvantage of TEA as compared with AFB is that a larger, more meticulous dissection is required to expose and control the branches of the infrarenal aorta. For this reason, some surgeons may opt for AFB even if the occlusive process is limited to the infrarenal aorta and common iliac arteries.

Finally, aortoiliac TEA should not be performed if occlusive plaques involve the more distal external iliac and femoral arteries. The "tail" of the atheroma in the common iliac artery may extend into the orifice of the external iliac artery, and this tongue usually is removed easily during the course of the procedure. However, if diffuse disease exists in the more distal external iliac and femoral arteries, AFB is a more suitable alternative.

AFB is the most common open surgical alternative used to treat AIOD. In the early experience of aortic surgery, unilateral AFB or even aortoiliac bypass (AIB) often was performed to limit the extent of the procedure. However, as more experience was gained with these operations, using the common femoral arteries as the outflow target clearly produced better long-term patency results. Unilateral AFB is performed infrequently today because the extremity that was neglected initially seldom is truly healthy and invariably demonstrates symptoms from progressive atherosclerosis. Therefore, bilateral AFB is appropriate to avoid the need for subsequent inflow operative procedures on the limb that demonstrates less extensive occlusive disease.

The original approach to AFB was transabdominal. As an alternative approach, retroperitoneal exposure of the aorta can be used to avoid entering the peritoneum. Some authors have advocated this approach on the basis of a theoretical advantage of fewer pulmonary problems, more rapid resolution of postoperative ileus, and fewer days in the hospital. Other studies have not supported this proposed benefit.

In some circumstances, a bypass serving both legs can be constructed using a single common iliac artery as the donor site. This procedure can be performed through either a transperitoneal or a retroperitoneal approach.

For higher-risk patients who are less likely to tolerate an abdominal operation, extra-anatomic bypass was developed in the mid 1960s. Axillobifemoral bypass provided an extracavitary means of improving blood flow to the lower extremities. This procedure proved especially useful in the treatment of aortic graft infections. However, the long-term patency of extra-anatomic bypass is distinctly inferior to that of conventional AFB.

With the advent of percutaneous transluminal angioplasty (PTA) and stenting, excellent minimally invasive alternatives to conventional open reconstructive surgery now are available. If applied to the appropriate anatomic problem, the results of iliac angioplasty/stent placement rival open surgical results. For isolated segmental common iliac artery stenoses, angioplasty/stenting rivals open surgical results. However, for occlusive disease that diffusely involves the aortoiliac segment, direct open surgical repair still offers the best long-term outcome. However, through catheter-based treatments (angioplasty/stenting), patients with significant operative risk due to comorbid diseases can be offered therapy.

Preoperative preparation

Because most patients with AIOD are older than 50 years, finding associated ischemic heart disease is not uncommon, even if classic anginal symptoms are not present. Hertzer et al found that most patients undergoing aortic operations for arterial occlusive disease had diseased coronary arteries when coronary arteriography was performed. Moreover, Porter et al found a significant incidence of occlusive plaques in the carotid arteries in a similar group of patients. Clearly, AIOD does not exist in a vacuum. However, despite the association of coronary and extracranial arterial occlusive disease with PAD, it is clear that not every patient needs an extensive preoperative evaluation before undergoing aortic surgery.

Preoperative cardiac evaluations are reserved for patients with either an abnormal finding on electrocardiography (ECG) and/or a history of new-onset or unstable angina or with symptoms of ventricular dysfunction (orthopnea, dyspnea on exertion). Patients who have had coronary angioplasty or bypass or who have a history of stable angina on appropriate medication probably do not need a preoperative cardiac evaluation, unless a change has occurred in either exercise tolerance or anginal pattern.

Immediately before the induction of anesthesia, the anesthesiologist places an epidural catheter. Although the catheter is not used during the procedure, the analgesic relief provided by instillation of narcotic and local anesthetic agents in the postoperative period is invaluable.

In addition, a systemic dose of a perioperative cephalosporin is administered intravenously before the skin incision is made. The antibiotic is continued postoperatively for 24-28 hours to lower the risk of graft infection.

Procedural details

Both TEA and AFB can be performed through either a longitudinal midline or a transverse intra-abdominal incision and even may be performed via a retroperitoneal exposure to the aorta. More dissection is needed with TEA. Total circumferential mobilization of the infrarenal aorta and common iliac arteries is required in order to perform aortoiliac TEA. The proximal extent of the dissection is the level of the renal arteries as long as the occlusive plaques do not extend proximally and impinge on the orifices of these vessels. If occlusive disease extends cephalad to the renal arteries, the dissection must be carried proximally to the origin of the superior mesenteric artery (SMA) to allow placement of the aortic occluding clamp at the base of this vessel.

An alternative approach for suprarenal control of the aorta is placement of the aortic cross clamp above the level of the celiac axis, a maneuver that is not difficult and is quite familiar to vascular surgeons. The lumbar, middle sacral, and inferior mesenteric (IMA) arteries must be managed using vessel loops to control back bleeding when the aorta is opened. Take care to identify and preserve any accessory renal arterial branches that may be present in as many as 20% of patients. In addition, the proximal portion of the external iliac and hypogastric arteries should be dissected adequately to allow placement of occluding clamps on these vessels distal enough from the origin to view the proximal portion of the external iliac artery

The difficult portion of the dissection occurs around the distal aorta and proximal common iliac arteries. The inferior vena cava and common iliac veins may be quite adherent to the arteries at this point, and care must be taken to avoid injury to these veins. After the dissection is completed, 5000 units of intravenous heparin are administered prior to arterial occlusion.

The distal clamps are placed first to reduce the incidence of atheroembolism that may occur following application of the aortic clamp. A longitudinal incision is made in the aorta, extending from 2 cm distal to the aortic occluding clamp proximally to 2 cm proximal to the aortic bifurcation distally. Place the line of incision on the right side of the anterior surface of the aorta to avoid the origin of the IMA. The endarterectomy plane is easily established where the atheromatous disease is most severe. Grasp the plaque and gently push away the remaining arterial wall. The dissection is continued distally until the bifurcation is reached, and the appropriate plane is continued into the orifice of each common iliac artery.

The iliac artery may be incised longitudinally (if the length of the common iliac is long), or even transversely, directly over the common iliac bifurcation. The author prefers a longitudinal incision extending from the proximal common iliac artery 2 cm from the origin to the iliac bifurcation because it affords the surgeon a better view of the endarterectomized surface and the endarterectomy endpoint. A bridge of arterial wall is preserved between the abdominal aortic incision and the common iliac incisions.

Once the entire plaque is mobilized in the common iliac, the entire specimen may be pulled in a cephalad direction and removed entirely as a single specimen that bears somer esemblance to a pair of pants. Take care to examine the distal endpoint in the iliac artery. A tongue of atheroma may continue into the origin of the external iliac and hypogastric arteries. This tail of atheroma must be excised in a more superficial plane to avoid extending the endarterectomy into the deeper plane used to perform TEA. The plane of the atheroma actually is easy to discern because the atheroma usually is a darker yellow color and has a different consistency than the more normal adherent intima.

After any remaining plaque and/or strands of media are removed, the arteriotomies are closed with continuous polypropylene sutures. If the aorta is small (<2 cm), a prosthetic zero-porosity Dacron patch is used to avoid the narrowing that may occur during primary closure of a longitudinal arteriotomy. Once blood flow has been restored, femoral pulses should be palpated to confirm the presence of adequate inflow.

A similar aortic exposure is used to perform AFB. In addition, the common femoral artery, the proximal superficial femoral artery (SFA), and the proximal deep femoral (profunda femoris) artery are mobilized through longitudinal groin incisions that are made just lateral to the femoral pulse. If the pulse is not present, the proper line of incision is found by measuring 3-4 fingerbreadths lateral to the pubic tubercle.

Cover the skin in a povidone-iodine–impregnated plastic drape to help avoid skin contact with the prosthetic graft. The infrarenal aorta immediately adjacent to the renal arteries is mobilized. Circumferential mobilization of the aorta is not necessary. The common femoral artery and its branches are mobilized from the inguinal ligament to the bifurcation, exposing enough of the SFA and the deep femoral artery to allow placement of an arterial occluding clamp.

The aortic anastomosis may be performed in either an end-to-end or an end-to-side configuration using continuous polypropylene suture. Although partially occluding aortic clamps have been used in performing end-to-side anastomoses, a better view of the aortic lumen is obtained with the use of proximal and distal clamps that totally occlude the aorta.

If the aorta is filled with atherosclerotic debris that appears loose and may embolize when flow is restored, perform an end-to-end aortic anastomosis and oversew the distal aorta. The configuration of the proximal anastomosis is not as important as its location. The anastomosis to the aorta must be placed near the renal arteries to help avoid recurrent atheromatous and/or aneurysmal disease that may involve infrarenal aorta that remains proximal to the aortic anastomosis.

Once the proximal anastomosis is completed and no bleeding is present, the limbs of the prosthetic graft are passed carefully through retroperitoneal tunnels that were made before the patient received intravenous heparin. The tunnels are made directly anterior to the iliac arteries and posterior to the ureters. The circumflex iliac veins must be avoided during creation of the tunnel and passage of the graft limbs. Partial incision of the inguinal ligament may aid in constructing the tunnel and identifying these large troublesome veins.

The common femoral artery is incised longitudinally, and a conventional end-to-side femoral anastomosis is performed using continuous polypropylene suture. Take care to examine the origins of the two outflow branches of the common femoral artery (ie, the SFA and the deep femoral artery). Not uncommonly, the SFA has significant occlusive disease. If the SFA is occluded, any stenosis in the proximal portion of the deep femoral artery must be repaired to insure adequate long-term patency of the aortic graft limb. If the common femoral artery is severely diseased, limited local TEA may need to be performed to facilitate an adequate femoral anastomosis.

Postoperative care

In the past, all patients were monitored in an intensive care unit (ICU) for the first 24-48 hours following an aortic operation. In the last decade, it has become increasingly common for patients undergoing operations for occlusive disease to avoid the ICU and receive their postoperative care on a regular surgical floor.

For patients with hemodynamic concerns, systemic arterial paressure and pulmonary capillary wedge pressure (PCWP) are helpful guides for planning intravenous fluid requirements. In addition, hourly urinary output through a bladder catheter is recorded. Although significant blood loss is not common, the hematocrit is monitored every 6-12 hours during the first 24 hours.

If the operation has proceeded smoothly, perform extubation at the end of the procedure. Preoperative pulmonary function tests help to predict which patients are likely to develop postoperative respiratory problems. When the forced expiratory volume in 1 second (FEV1) is less than 1 L, one can anticipate difficult respiratory problems associated with conventional aortic surgical approaches through midline incisions. For such cases, a transverse intra-abdominal or retroperitoneal incision may help to reduce postoperative respiratory complications.

Most large fluid shifts occur following aortic surgery and are related to the size of the dissection and the length of the operation, as well as the amount of intraoperative blood loss. Patients tend to gain significant "wet weight" during the first 48 hours postoperatively. By the beginning of the third postoperative day, mobilization of the excess water back into the intravascular compartment begins to occur. Urine output increases, PCWP rises, and hematocrit may drift downward.

Also monitor the perfusion to the lower extremities carefully. If pedal pulses cannot be palpated as a consequence of SFA occlusive disease, monitor Doppler flow as well as the ankle-brachial index (ABI). After successful revascularization, the ABI should increase by at least 15%.

Complications

Several complications are related to both aortoiliac TEA and AFB, and others are associated only with one or the other. Perioperative thrombosis may be a complication of either procedure and generally is related to technical problems. For example, a plaque that dissects, causing restriction in blood flow and subsequent thrombosis, may occur as a complication of either procedure. Visualization of endarterectomy endpoints and suturing of plaques that may elevate when blood flow is restored may help to reduce the risk of dissection and subsequent thrombosis.

Intraoperative atheroembolism is another complication that may occur during surgical dissection and mobilization of the vessels or following release of the occluding clamps during reperfusion. Meticulous dissection during mobilization of the arteries is imperative. Furthermore, placement of the distal occluding clamps before application of the proximal clamps may help to reduce the risk of atheroembolism that is inherent during any aortic operation.

Injury to adjacent structures (ie, duodenum, inferior vena cava, iliac veins, ureters) usually is easy to avoid with careful technique. However, care must be used with mechanical retractors to avoid inadvertent injury to adjacent structures. Care is necessary both in the retroperitoneum and in the groin to avoid injury to nerves adjacent to major vessels.

Careful closure of groin wounds is necessary in order to avoid a lymphocele, which can lead to graft infection.

A specific complication related to the use of prosthetic material for AFB is the development of aortic graft infection, which occurs in 0.5-3% of cases. Usually, presentation of the infection follows the aortic procedure by a significant length of time (20-24 months). Most commonly, a complication of healing in the groin wound is the first sign that a serious, life-threatening, and limb-threatening problem must be dealt with.

Graft infections can be classified into two groups, depending on the etiologic microbial involved. The more virulent organisms (ie, Staphylococcus aureus, gram-negative bacilli) usually are responsible for causing a more severe type of clinical infection. When systemic signs of sepsis occur with graft infection, a virulent organism is present.

On the other hand, a significant number of graft infections are caused by Staphylococcus epidermidis. These infections are much more indolent, and the extent of graft involvement may be harder to determine. Even with the most skilled physician, the mortality after treatment of aortic graft infection is 11-27%. Moreover, the risk of amputation following graft infection is almost as high.

Major complications rates associated with catheter-based treatments (PTA/stenting) for aortoiliac occlusive disease range from 2.3-17%. The problem can occur in the target vessel, the access site, or even other arteries that are far removed anatomically (ie, atheroembolism). These complications include dissection, acute thrombosis, atheroembolism, and even arterial perforation. Complications related to the contrast agent (ie, anaphylaxis [rarely] or contrast-induced renal dysfunction) are uncommon.

Previous
Next

Long-Term Monitoring

In general, the results of therapy for AIOD are excellent, but patients still need follow-up care at regular intervals. See patients every 3-6 months for the first year and every 6-12 months thereafter. If a prosthetic graft has been implanted, a lifelong risk of graft infection exists that the patient must recognize. Moreover, oral antibiotic prophylaxis is appropriate before dental procedures, urologic instrumentation, sigmoidoscopy, or other gastrointestinal surgical procedures.

Previous
 
Contributor Information and Disclosures
Author

Kenneth E McIntyre, Jr, MD Professor of Surgery, Chief, Division of Vascular Surgery, University of Nevada School of Medicine; Chief, Surgical Service, Chief, Vascular Surgery, Veterans Administration of Southern Nevada

Kenneth E McIntyre, Jr, MD is a member of the following medical societies: Society for Vascular Surgery, Southern Association for Vascular Surgery, Society for Clinical Vascular Surgery, American College of Surgeons

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Travis J Phifer, MD 

Travis J Phifer, MD is a member of the following medical societies: American College of Emergency Physicians, American College of Surgeons, American Medical Association, Association for Academic Surgery, Society for Academic Emergency Medicine, Society for Vascular Surgery, Society of Critical Care Medicine

Disclosure: Nothing to disclose.

Chief Editor

Vincent Lopez Rowe, MD Professor of Surgery, Program Director, Vascular Surgery Residency, Department of Surgery, Division of Vascular Surgery, Keck School of Medicine of the University of Southern California

Vincent Lopez Rowe, MD is a member of the following medical societies: American College of Surgeons, American Heart Association, Society for Vascular Surgery, Vascular and Endovascular Surgery Society, Society for Clinical Vascular Surgery, Pacific Coast Surgical Association, Western Vascular Society

Disclosure: Nothing to disclose.

Additional Contributors

Jeffrey Lawrence Kaufman, MD Associate Professor, Department of Surgery, Division of Vascular Surgery, Tufts University School of Medicine

Jeffrey Lawrence Kaufman, MD is a member of the following medical societies: Alpha Omega Alpha, American College of Surgeons, American Society for Artificial Internal Organs, Association for Academic Surgery, Association for Surgical Education, Massachusetts Medical Society, Phi Beta Kappa, Society for Vascular Surgery

Disclosure: Nothing to disclose.

References
  1. Aboyans V, Desormais I, Lacroix P, Salazar J, Criqui MH, Laskar M. The general prognosis of patients with peripheral arterial disease differs according to the disease localization. J Am Coll Cardiol. 2010 Mar 2. 55(9):898-903. [Medline].

  2. Dos Santos JC. Sur la desobstruction des thrombus arterielles anciennes. Mem Acad Chir. 1947. 73:409.

  3. Wylie EJ. Thromboendarterectomy for arteriosclerotic thrombosis of major arteries. Surgery. 1952. 23:275-292. [Medline].

  4. Dotter C, Judkins M. Transluminal treatment of arteriosclerotic obstruction: Description of a new technique and a preliminary report of its application. Circulation. 1964 Nov. 30:654-70. [Medline].

  5. Grüntzig A, Hopff H. [Percutaneous recanalization after chronic arterial occlusion with a new dilator-catheter (modification of the Dotter technique) (author's transl)]. Dtsch Med Wochenschr. 1974 Dec 6. 99(49):2502-10, 2511. [Medline].

  6. Palmaz JC, Sibbitt RR, Reuter SR, et al. Expandable intraluminal graft: a preliminary study. Work in progress. Radiology. 1985 Jul. 156(1):73-7. [Medline].

  7. Indes JE, Pfaff MJ, Farrokhyar F, Brown H, Hashim P, Cheung K, et al. Clinical outcomes of 5358 patients undergoing direct open bypass or endovascular treatment for aortoiliac occlusive disease: a systematic review and meta-analysis. J Endovasc Ther. 2013 Aug. 20 (4):443-55. [Medline].

  8. [Guideline] Society for Vascular Surgery Lower Extremity Guidelines Writing Group, Conte MS, Pomposelli FB, Clair DG, Geraghty PJ, McKinsey JF, et al. Society for Vascular Surgery practice guidelines for atherosclerotic occlusive disease of the lower extremities: management of asymptomatic disease and claudication. J Vasc Surg. 2015 Mar. 61 (3 Suppl):2S-41S. [Medline]. [Full Text].

  9. Weitz JI, Byrne J, Clagett GP. Diagnosis and treatment of chronic arterial insufficiency of the lower extremities: a critical review. Circulation. 1996 Dec 1. 94(11):3026-49. [Medline].

  10. Gardner AW, Poehlman ET. Exercise rehabilitation programs for the treatment of claudication pain. A meta-analysis. JAMA. 1995 Sep 27. 274(12):975-80. [Medline].

  11. Blaisdell FW, Hall AD. Axillary femoral bypass for lower extremity ischemia. Surgery. 1963. 54:563. [Medline].

  12. Iida O, Soga Y, Takahara M, Kawasaki D, Yamauchi Y, Suzuki K, et al. Efficacy of the S.M.A.R.T. Control vs. Other Stents for Aortoiliac Occlusive Disease in Contemporary Clinical Practice. J Endovasc Ther. 2013 May. 20(3):431-9. [Medline].

  13. Goverde PC, Grimme FA, Verbruggen PJ, Reijnen MM. Covered endovascular reconstruction of aortic bifurcation (CERAB) technique: a new approach in treating extensive aortoiliac occlusive disease. J Cardiovasc Surg (Torino). 2013 Jun. 54(3):383-7. [Medline].

  14. Szilagyi DE, Smith RF, Elliott JP, et al. Infection in arterial reconstruction with synthetic grafts. Ann Surg. 1972 Sep. 176(3):321-33. [Medline].

  15. TASC Working Group. Endovascular procedures for intermittent claudication. J Vasc Surg. 2000. 31:S97-S112.

  16. Taylor Jr LM, Moneta GL, Porter JM. Natural history and non-operative treatment of chronic lower extremity ischemia. Vasc Surg. 2000. 928-43.

  17. Yeager RA, Moneta GL, Taylor LM Jr, Harris EJ Jr, McConnell DB, Porter JM. Improving survival and limb salvage in patients with aortic graft infection. Am J Surg. 1990 May. 159 (5):466-9. [Medline].

  18. Baker JD. Physiologic studies to document severity of aortoiliac occlusive disease. Ernst CB, Stanley JC, eds. Current Therapy in Vascular Surgery. 4th ed. St Louis, MO: Mosby-Year Book; 2001.

  19. Ballard JL, Bergan JJ, Singh P, et al. Aortoiliac stent deployment versus surgical reconstruction: analysis of outcome and cost. J Vasc Surg. 1998 Jul. 28(1):94-101; discussion 101-3. [Medline].

  20. Ballard JL, Sparks SR, Taylor FC, et al. Complications of iliac artery stent deployment. J Vasc Surg. 1996 Oct. 24(4):545-53; discussion 553-5. [Medline].

  21. Barbera L, Mumme A, Metin S, et al. Operative results and outcome of twenty-four totally laparoscopic vascular procedures for aortoiliac occlusive disease. J Vasc Surg. 1998 Jul. 28(1):136-42. [Medline].

  22. Bosch JL, Hunink MG. Meta-analysis of the results of percutaneous transluminal angioplasty and stent placement for aortoiliac occlusive disease. Radiology. 1997 Jul. 204(1):87-96. [Medline].

  23. Brewster DC. Current controversies in the management of aortoiliac occlusive disease. J Vasc Surg. 1997 Feb. 25(2):365-79. [Medline].

  24. Brewster DC, Darling RC. Optimal methods of aortoiliac reconstruction. Surgery. 1978 Dec. 84(6):739-48. [Medline].

  25. Cambria RP, Brewster DC, Abbott WM, et al. Transperitoneal versus retroperitoneal approach for aortic reconstruction: a randomized prospective study. J Vasc Surg. 1990 Feb. 11(2):314-24; discussion 324-5. [Medline].

  26. Chang IS, Park KB, Do YS, Park HS, Shin SW, Cho SK, et al. Heavily calcified occlusive lesions of the iliac artery: long-term patency and CT findings after stent placement. J Vasc Interv Radiol. 2011 Aug. 22 (8):1131-7.e1. [Medline].

  27. Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. BMJ. 1994 Jan 8. 308 (6921):81-106. [Medline]. [Full Text].

  28. Criqui MH, Fronek A, Barrett-Connor E, et al. The prevalence of peripheral arterial disease in a defined population. Circulation. 1985 Mar. 71(3):510-5. [Medline].

  29. Criqui MH, Langer RD, Fronek A, et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med. 1992 Feb 6. 326(6):381-6. [Medline].

  30. DeBakey ME, Cooley DA, Crawford ES, Morris GC Jr. Clinical application of a new flexible knitted Dacron arterial substitute. 1958. Am Surg. 2008 May. 74 (5):381-6. [Medline].

  31. Donaldson MC, Louras JC, Bucknam CA. Axillofemoral bypass: a tool with a limited role. J Vasc Surg. 1986 May. 3(5):757-63. [Medline].

  32. el-Massry S, Saad E, Sauvage LR, et al. Axillofemoral bypass with externally supported, knitted Dacron grafts: a follow-up through twelve years. J Vasc Surg. 1993 Jan. 17(1):107-14; discussion 114-5. [Medline].

  33. Ernst E, Fialka V. A review of the clinical effectiveness of exercise therapy for intermittent claudication. Arch Intern Med. 1993 Oct 25. 153(20):2357-60. [Medline].

  34. Funovics MA, Lackner B, Cejna M, et al. Predictors of long-term results after treatment of iliac artery obliteration by transluminal angioplasty and stent deployment. Cardiovasc Intervent Radiol. 2002 Sep-Oct. 25(5):397-402.

  35. Harrington ME, Harrington EB, Haimov M, et al. Iliofemoral versus femorofemoral bypass: the case for an individualized approach. J Vasc Surg. 1992 Dec. 16(6):841-52; discussion 852-4. [Medline].

  36. Hiatt WR, Hoag S, Hamman RF. Effect of diagnostic criteria on the prevalence of peripheral arterial disease. The San Luis Valley Diabetes Study. Circulation. 1995 Mar 1. 91(5):1472-9. [Medline].

  37. Ichihashi S, Higashiura W, Itoh H, Sakaguchi S, Nishimine K, Kichikawa K. Long-term outcomes for systematic primary stent placement in complex iliac artery occlusive disease classified according to Trans-Atlantic Inter-Society Consensus (TASC)-II. J Vasc Surg. 2011 Apr. 53(4):992-9. [Medline].

  38. Jackson MR, Clagett GP. Antithrombotic therapy in peripheral arterial occlusive disease. Chest. 2001 Jan. 119(1 Suppl):283S-299S. [Medline].

  39. Lee GC, Yang SS, Park KM, Park Y, Kim YW, Park KB, et al. Ten year outcomes after bypass surgery in aortoiliac occlusive disease. J Korean Surg Soc. 2012 Jun. 82(6):365-9. [Medline]. [Full Text].

  40. Legemate DA, Teeuwen C, Hoeneveld H, et al. Value of duplex scanning compared with angiography and pressure measurement in the assessment of aortoiliac arterial lesions. Br J Surg. 1991 Aug. 78(8):1003-8. [Medline].

  41. Malone JM, Moore WS, Goldstone J. The natural history of bilateral aortofemoral bypass grafts for ischemia of the lower extremities. Arch Surg. 1975 Nov. 110(11):1300-6. [Medline].

  42. McKenna M, Wolfson S, Kuller L. The ratio of ankle and arm arterial pressure as an independent predictor of mortality. Atherosclerosis. 1991 Apr. 87(2-3):119-28. [Medline].

  43. Messina LM. Endarterectomy for atherosclerotic aortoiliac occlusive disease. Ernst CB, Stanley JC, eds. Current Therapy in Vascular Surgery. 4th ed. St Louis, MO: Mosby-Year Book; 2001. 381-4.

  44. Newman AB, Siscovick DS, Manolio TA, et al. Ankle-arm index as a marker of atherosclerosis in the Cardiovascular Health Study. Cardiovascular Heart Study (CHS) Collaborative Research Group. Circulation. 1993 Sep. 88(3):837-45. [Medline].

  45. Passman MA, Taylor LM, Moneta GL, et al. Comparison of axillofemoral and aortofemoral bypass for aortoiliac occlusive disease. J Vasc Surg. 1996 Feb. 23(2):263-9; discussion 269-71. [Medline].

  46. Pentecost MJ, Criqui MH, Dorros G, et al. Guidelines for peripheral percutaneous transluminal angioplasty of the abdominal aorta and lower extremity vessels. A statement for health professionals from a special writing group of the Councils on Cardiovascular Radiology, Arteriosclerosis, Cardio. Circulation. 1994 Jan. 89(1):511-31. [Medline].

  47. Prendiville EJ, Burke PE, Colgan MP, et al. The profunda femoris: a durable outflow vessel in aortofemoral surgery. J Vasc Surg. 1992 Jul. 16(1):23-9. [Medline].

  48. Regensteiner JG, Steiner JF, Hiatt WR. Exercise training improves functional status in patients with peripheral arterial disease. J Vasc Surg. 1996 Jan. 23(1):104-15. [Medline].

  49. Ross R. The pathogenesis of atherosclerosis--an update. N Engl J Med. 1986 Feb 20. 314(8):488-500. [Medline].

  50. Said S, Mall J, Peter F, Muller JM. Laparoscopic aortofemoral bypass grafting: human cadaveric and initial clinical experiences. J Vasc Surg. 1999 Apr. 29(4):639-48. [Medline].

  51. Schafer AL. Antiplatelet therapy. Am J Med. 1996 Aug. 101(2):199-209. [Medline].

  52. Schmalstieg J, Zeller T, Tübler T, Sixt S, Schwencke C, Sandstede J, et al. Long term data of endovascularly treated patients with severe and complex aortoiliac occlusive disease. J Cardiovasc Surg (Torino). 2012 Jun. 53(3):291-300. [Medline].

  53. Schneider PA. Endovascular or open surgery for aortoiliac occlusive disease?. Cardiovasc Surg. 2002 Aug. 10(4):378-82. [Medline].

  54. Sharp WJ, Hoballah JJ, Mohan CR, et al. The management of the infected aortic prosthesis: a current decade of experience. J Vasc Surg. 1994 May. 19(5):844-50. [Medline].

  55. Stoney RJ, Reilly LM. Endarterectomy for aortoiliac occlusive disease. Ernst CB, Stanley JC, eds. Current Therapy in Vascular Surgery. St Louis, MO: Mosby-Year Book; 1987. 157.

  56. Szilagyi DE, Elliott JP, Smith RF. A thirty-year survey of the reconstructive surgical treatment of aortoiliac occlusive disease. J Vasc Surg. 1986 Mar. 3(3):421-36. [Medline].

 
Previous
Next
 
Type I atherosclerosis with occlusive disease limited to the infrarenal aorta and common iliac arteries.
Large collateral vessels confirm hemodynamic significance of left common iliac stenosis.
Successful treatment of focal high-grade left common iliac stenosis with Palmaz stent.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.